8-K: Revance Therapeutics Reports Q3 2024 Results, Merger Agreement Extended

Revance Therapeutics announced its third quarter 2024 financial results, a merger agreement with Crown Laboratories, and an extension to the tender offer commencement date.

Summary

• Revance Therapeutics reported a total net revenue of $59.9 million for the third quarter of 2024, an 11% increase compared to $54.1 million in the same period of 2023.
• The revenue increase was primarily driven by higher sales volumes of DAXXIFY and the RHA Collection of dermal fillers, although average selling prices for both product lines decreased.
• RHA Collection revenue was $30.5 million, DAXXIFY revenue was $28.3 million, and collaboration revenue was $1.1 million for the quarter.
• Total net revenue for the first nine months of 2024 reached $177.2 million, up from $154.3 million in the same period of 2023.
• Selling, general, and administrative expenses decreased to $62.6 million for the quarter and $197.3 million for the nine months, primarily due to lower stock-based compensation and sales and marketing expenses.
• Research and development expenses increased to $11.4 million for the quarter and decreased to $41.7 million for the nine months, due to the capitalization of DAXXIFY manufacturing expenses.
• The net loss from continuing operations was $38.1 million for the quarter and $125.1 million for the nine months.
• Cash, cash equivalents, and short-term investments totaled $184.1 million as of September 30, 2024.
• The company has withdrawn its 2024 financial guidance due to the pending merger with Crown Laboratories and will not hold a conference call to discuss the results.
• The tender offer commencement date for the merger has been extended to November 12, 2024, or another mutually agreed date.
• Revance has entered into an exclusive distribution agreement with Teoxane for DAXXIFY in Australia and New Zealand, expiring December 31, 2040.
• DAXXIFY has been approved in Mainland China for the temporary improvement of glabellar lines.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the net loss, the withdrawal of financial guidance, and the delay in the merger tender offer. However, there are some positives such as revenue growth and the approval of DAXXIFY in China.

Positives

• Total net revenue increased by 11% year-over-year, driven by higher sales volumes of DAXXIFY and the RHA Collection.
• Revance secured an exclusive distribution agreement with Teoxane for DAXXIFY in Australia and New Zealand.
• DAXXIFY received approval in Mainland China, expanding its market reach.
• Selling, general, and administrative expenses decreased for both the quarter and the nine-month period.
• The company has $184.1 million in cash, cash equivalents, and short-term investments.

Negatives

• Average selling prices for both DAXXIFY and the RHA Collection decreased.
• The company reported a net loss from continuing operations of $38.1 million for the quarter and $125.1 million for the nine months.
• The tender offer commencement date for the merger with Crown Laboratories has been extended.
• Revance has withdrawn its 2024 financial guidance and will not hold a conference call to discuss the results.

Risks

• The merger with Crown Laboratories is subject to risks and uncertainties, including the possibility of competing offers and the failure to complete the merger.
• The company's financial performance is subject to macroeconomic factors and market conditions.
• There are risks associated with the commercialization of DAXXIFY and the RHA Collection, including market acceptance and competition.
• The company faces risks related to regulatory approvals, manufacturing, and supply chain.
• The company is subject to risks related to intellectual property, product liability, and cybersecurity incidents.

Future Outlook

Revance has withdrawn its 2024 financial guidance due to the pending merger with Crown Laboratories and will not hold a conference call to discuss the results.

Industry Context

The announcement reflects the ongoing consolidation in the aesthetics industry, with Revance seeking to merge with Crown Laboratories. The approval of DAXXIFY in China is a significant milestone for the company, expanding its global reach in the competitive botulinum toxin market. The partnership with Teoxane for distribution in Australia and New Zealand is also a strategic move to expand its international presence.

Comparison to Industry Standards

• Revance's revenue growth of 11% year-over-year is a positive sign, but the decrease in average selling prices for both DAXXIFY and RHA Collection is a concern. Competitors like AbbVie (Allergan) and Merz also face pricing pressures in the aesthetics market.
• The net loss of $38.1 million for the quarter is significant, and the company needs to improve its profitability. Other companies in the sector, such as Evolus, also face challenges in achieving profitability.
• The merger with Crown Laboratories is a strategic move to create a larger, more diversified company. Similar mergers and acquisitions have been seen in the industry as companies seek to expand their product portfolios and market reach.
• The approval of DAXXIFY in China is a major achievement, as the Chinese market is a significant growth opportunity for aesthetics companies. Competitors like Ipsen and Hugel also have a presence in the Chinese market.
• The distribution agreement with Teoxane for Australia and New Zealand is a positive step for Revance, as it expands its international footprint. Other companies in the sector also rely on distribution partnerships to reach new markets.

Stakeholder Impact

• Shareholders may be concerned about the net loss and the delay in the merger.
• Employees may be affected by the merger and any potential restructuring.
• Customers may benefit from the expanded availability of DAXXIFY and the RHA Collection.
• Suppliers may be impacted by the merger and any changes in the supply chain.
• Creditors may be concerned about the company's financial performance.

Next Steps

• The tender offer for the merger with Crown Laboratories is expected to commence by November 12, 2024.
• Revance will continue to commercialize DAXXIFY and the RHA Collection of dermal fillers.
• Revance will work with Teoxane to distribute DAXXIFY in Australia and New Zealand.
• Revance will work with Shanghai Fosun Pharmaceutical to commercialize DAXXIFY in China.

Key Dates

Keywords

Revance Therapeutics, DAXXIFY, RHA Collection, Merger, Crown Laboratories, Tender Offer, Financial Results, Dermal Fillers, Aesthetics, China Approval, Distribution Agreement